4.3 Article

Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling

Journal

CLINICAL & EXPERIMENTAL METASTASIS
Volume 38, Issue 3, Pages 321-335

Publisher

SPRINGER
DOI: 10.1007/s10585-021-10093-z

Keywords

Axl; Bone metastasis; Receptor tyrosine kinase; Osteoclastogenesis

Categories

Funding

  1. National Institute of Health [1R01CA197477]

Ask authors/readers for more resources

The study found that inhibiting Axl in prostate and breast cancer cells can significantly reduce metastatic potential, and inhibiting Axl signaling in osteoclast precursor cells can also reduce the formation of mature osteoclasts. In vivo, Axl knockdown in prostate and breast cancer cells significantly suppressed the formation and progression of bone metastases. Therefore, therapeutic targeting of Axl may impair tumor metastasis to the bones through neoplastic and host cell signaling axes.
Approximately 90% of cancer-related deaths result from cancer metastasis. In prostate and breast cancers, bone is the most common site of cancer cell dissemination. Key steps in the metastatic cascade are promoted through upregulation of critical cell signaling pathways in neoplastic cells. The present study assessed the role of the receptor tyrosine kinase Axl in prostate and breast cancer cell metastasis to bones using (i) Axl knockdown neoplastic cells and osteoclast progenitor cells in vitro, (ii) intracardiac injection of Axl knockdown tumor cells in vivo, and (iii) selective Axl inhibitor BGB324. Axl inhibition in neoplastic cells significantly decreased their metastatic potential, and suppression of Axl signaling in osteoclast precursor cells also reduced the formation of mature osteoclasts. In vivo, Axl knockdown in prostate and breast cancer cells significantly suppressed the formation and progression of bone metastases. Hence, therapeutic targeting of Axl may impair tumor metastasis to the bones through neoplastic and host cell signaling axes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available